載入中
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
前收盤價
US$1.58
−US$0.10 · -5.95%
盤前
US$1.54
−US$0.04 · -2.53%
10月12日 上午9:15 ET
盤中時間採用ET。市場資料可能有所延遲。
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
日內區間
目前US$1.58
52週區間
目前US$1.58
盤中時間採用ET。市場資料可能有所延遲。
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
日內區間
目前US$1.58
52週區間
目前US$1.58
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5665.1萬 USD | 5129.2萬 USD | 3929.5萬 USD | 2246.9萬 USD | 1303.6萬 USD |
| 銷貨成本 | 831.1萬 USD | 833.4萬 USD | 625.6萬 USD | 499.9萬 USD | 364萬 USD |
| 毛利 | 4834萬 USD | 4295.8萬 USD | 3303.9萬 USD | 1747萬 USD | 939.6萬 USD |
| 研究與開發 | 1113.2萬 USD | 1113.1萬 USD | 1163.3萬 USD | 995.2萬 USD | 750.1萬 USD |
| 銷售、一般及管理費用 | 8847.3萬 USD | 9131.7萬 USD | 6450.9萬 USD | 5004.5萬 USD | 2786.3萬 USD |
| 營業費用 | 9960.5萬 USD | 1.02億 USD | 7614.2萬 USD | 5999.7萬 USD | 3536.4萬 USD |
| 利息支出 | 582.7萬 USD | 439.7萬 USD | 179.9萬 USD | 16.5萬 USD | 221.9萬 USD |
| 折舊和攤銷 | 75.6萬 USD | 61.9萬 USD | 52.2萬 USD | 41.2萬 USD | 16.8萬 USD |
| 營業利益 | −5126.5萬 USD | −5949萬 USD | −4310.3萬 USD | −4252.7萬 USD | −2596.8萬 USD |
| 淨利 | −5330.6萬 USD | −5996.5萬 USD | −4119.9萬 USD | −4142.8萬 USD | −4307.8萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.30
上漲空間 172.15%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI202.5萬0.00%2.3兆 USD0.03%US$382.1+0.04%
iShares Russell 2000 ETFIWM63.79萬0.00%787.4億 USD0.19%US$278.59-0.13%
Vanguard Extended Market ETFVXF60.54萬0.00%954億 USD0.05%US$234.94-0.03%
iShares Russell 2000 Growth ETFIWO26.11萬0.00%139.17億 USD0.24%US$356.11-0.19%
Vanguard Russell 2000 ETFVTWO26.07萬0.00%180億 USD0.06%US$112.53-0.12%
iShares Micro-Cap ETFIWC8.21萬0.01%13.17億 USD0.60%US$182.4-0.33%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6萬0.05%1.17億 USD0.73%US$15.89-0.31%
Vanguard Russell 2000 Growth ETFVTWG5.16萬0.00%17億 USD0.06%US$260.17-0.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMVanguard Russell 2000 Growth ETFVTWGAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
